Anfield Capital Management, LLC Innoviva, Inc. Transaction History

Anfield Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$11.61 - $15.22 $417 - $547	36 Added 2.67%	1,386 $16,000
Q2 2022 Aug 09, 2022	BUY	$14.32 - $19.88 $2,062 - $2,862	144 Added 11.94%	1,350 $20,000
Q1 2022 May 13, 2022	BUY	$15.39 - $20.25 $10,157 - $13,365	660 Added 120.88%	1,206 $23,000
Q4 2021 Feb 03, 2022	BUY	$15.91 - $18.72 $8,034 - $9,453	505 Added 1231.71%	546 $9,000
Q3 2021 Nov 04, 2021	BUY	$13.06 - $17.24 $535 - $706	41 New	41 $1,000

228

79.1M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Anfield Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Anfield Capital Management, LLC with notifications on news.